RaySearch Laboratories AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr1.98.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr8.32.
During the past 12 months, the average EBIT per Share Growth Rate of RaySearch Laboratories AB was -1.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 121.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for RaySearch Laboratories AB's EBIT per Share or its related term are showing as below:
CHIX:RAYBs'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.4 Med: 12.55 Max: 121.6
Current: 121.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of RaySearch Laboratories AB was 121.60% per year. The lowest was -47.40% per year. And the median was 12.55% per year.
CHIX:RAYBs's 3-Year EBIT Growth Rate is ranked better than 97.92% of 529
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs CHIX:RAYBs: 121.60
RaySearch Laboratories AB (CHIX:RAYBs) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
RaySearch Laboratories AB EBIT per Share Related Terms
RaySearch Laboratories AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (CHIX:RAYBS) has a EBIT per Share of kr8.32 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RaySearch Laboratories AB and its competitors. According to the industry distribution chart, RaySearch Laboratories AB ranks #11 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 2.1%.
Is RaySearch Laboratories AB's EBIT per Share too high?
RaySearch Laboratories AB's current EBIT per Share is kr8.32. Based on the distribution chart, RaySearch Laboratories AB ranks #11 out of 529 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #11 out of 529 companies for EBIT per Share. This places RaySearch Laboratories AB in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current EBIT per Share is kr8.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr180.90, compared to a current price of kr234.70 — trading 29.7% above its estimated fair value. The current EBIT per Share is kr8.32. RaySearch Laboratories AB's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current EBIT per Share is kr8.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 29.7% above its estimated GF Value™ of kr180.90.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for CHIX:RAYBS:
EBIT per Share: kr8.32
GF Value™: kr180.90 vs. price of kr234.70 (29.7% above fair value)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
94GF Score
Get the complete analysis for CHIX:RAYBS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
